TY - JOUR AU - Mao, Yousheng AU - Yu, Zhentao AU - You, Bin AU - Fang, Wentao AU - Badgwell, Brian AU - Berry, Mark F. AU - Ceppa, DuyKhanh P. AU - Chen, Chun AU - Chen, Haiquan AU - Cuesta, Miguel A. AU - D’Journo, Xavier Benoit AU - Eslick, Guy D. AU - Fu, Jianhua AU - Fu, Xiangning AU - Gao, Shugeng AU - He, Jianxing AU - He, Jie AU - Huang, Yunchao AU - Jiang, Gening AU - Jiang, Zhongmin AU - Kim, Jae Y. AU - Li, Danqing AU - Li, Hui AU - Li, Shanqing AU - Liu, Deruo AU - Liu, Lunxu AU - Liu, Yongyu AU - Li, Xiaofei AU - Li, Yin AU - Mao, Weimin AU - Molena, Daniela AU - Morse, Christopher R. AU - Novoa, Nuria M. AU - Tan, Lijie AU - Tan, Qunyou AU - Toker, Alper AU - Tong, Ti AU - Wang, Qun AU - Weksler, Benny AU - Xu, Lin AU - Xu, Shidong AU - Yan, Tiansheng AU - Zhang, Lanjun AU - Zhang, Xingyi AU - Zhang, Xun AU - Zhang, Zhu AU - Zhi, Xiuyi AU - Zhou, Qinghua PY - 2018 TI - Society for Translational Medicine Expert consensus on the selection of surgical approaches in the management of thoracic esophageal carcinoma JF - Journal of Thoracic Disease; Vol 11, No 1 (January 26, 2019): Journal of Thoracic Disease Y2 - 2018 KW - N2 - Esophageal cancer (EC) is a highly prevalent malignancy in China. According to the data released by National Cancer Registry Center of China in 2015, the prevalence of EC was 21.17/100,000 in China in 2012, ranking fifth among all malignancies; the mortality rate was 15.58/100,000, ranking fourth. It is expected that there will be 477,900 new EC cases nationwide in 2015, whereas 375,000 people will die from EC (1,2). Worldwide, EC is the 8 th most common malignancy, with 416,000 new cases in 2012 (3). At present, EC treatment is based on multidisciplinary treatment, but surgery remains the most effective therapy in optimizing long-term prognosis in patients without metastatic disease. The ideal surgical approach is a matter of debate. UR - https://jtd.amegroups.org/article/view/25919